Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients Combination increases complete response rate to 24% compared to chemotherapy alone Bristol Myers Squibb’s PD-1 inhibitor Opdivo has scored a new win in the pre-surgery, non-small cell lung cancer (NSCLC) setting. Data presented at the virtual American Association for Cancer Research (AACR) annual meeting showcased results from the CheckMate-816 study, which evaluated Opdivo (nivolumab) plus chemotherapy in patients with early-stage NSCLC before surgery. The primary endpoints of the study were pathological complete response (pCR), defined as no residual viable tumour in the resected lung specimen and the sampled lymph node after surgery and event-free survival (EFS).